G1 Therapeutics, Inc.
GTHXDelisted Sep 18, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001560241
G1 Therapeutics, Inc. was delisted on Sep 18, 2024; its insiders filed their last Form 4 on Sep 18, 2024; 88 institutions reported holding it in 13F filings for Q2 2024, worth $45.5M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 88
- Q2 2024, +2 vs. previous quarter
- 13F value
- $45.5M
- Reported value at the end of Q2 2024
- Superinvestors holding
- 0
- At the end of Q2 2024
Superinvestors holding GTHX, Q2 2024
No superinvestor reported holding GTHX at the end of Q2 2024.
Latest insider trades
Open-market purchases and sales by G1 Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 8, 2024 (view filing) | Jul 5 | 3 days | Perry AndrewChief Commercial Officer | SSale | −1.34K | $2.51 | −$3.36K | −1.2%112.6K after | |
| Jul 8, 2024 (view filing) | Jul 5 | 3 days | Murdock Terry LChief Operating Officer | SSale | −2.48K | $2.51 | −$6.21K | −1.9%128.0K after | |
| Jul 8, 2024 (view filing) | Jul 5 | 3 days | Malik RajeshChief Medical Officer | SSale | −2.48K | $2.51 | −$6.21K | −1.5%159.3K after | |
| Jul 8, 2024 (view filing) | Jul 5 | 3 days | Avagliano MarkChief Business Officer | SSale | −2.64K | $2.51 | −$6.62K | −1.1%242.0K after | |
| Jul 8, 2024 (view filing) | Jul 5 | 3 days | Umstead John V.Chief Financial Officer | SSale | −527 | $2.51 | −$1.32K | −0.3%187.7K after | |
| Jul 8, 2024 (view filing) | Jul 5 | 3 days | Bailey John E. (Jack) Jr.President and CEO | SSale | −7.66K | $2.51 | −$19.2K | −1.4%549.7K after | |
| May 24, 2024 (view filing) | May 23 | 1 day | Thomas Monica R.Chief Legal & People Officer | SSale | −5.83K | $4.27 | −$24.9K | −5.0%109.8K after | |
| May 15, 2024 (view filing) | May 13 | 2 days | Perry AndrewChief Commercial Officer | SSale | −8.15K | $4.79 | −$39.0K | −9.4%79.0K after | |
| May 15, 2024 (view filing) | May 13 | 2 days | Umstead John V.Chief Financial Officer | SSale | −8.15K | $4.79 | −$39.0K | −5.1%153.2K after | |
| May 15, 2024 (view filing) | May 13 | 2 days | Murdock Terry LChief Operating Officer | SSale | −8.15K | $4.79 | −$39.0K | −7.9%95.5K after |
Top 10 13F holders, Q2 2024
The largest institutional positions in G1 Therapeutics, Inc. at the end of Q2 2024; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock Inc. | 3,082,031 | $7.03M | 0.00% | +2,410,004+358.6% | Added |
| Vanguard Group Inc | 2,491,109 | $5.68M | 0.00% | +409,536+19.7% | Added |
| Woodline Partners LP | 1,362,354 | $3.11M | 0.03% | +1,362,354 | New |
| Renaissance Technologies LLC | 1,245,180 | $2.84M | 0.00% | +341,480+37.8% | Added |
| Geode Capital Management, LLC | 1,079,645 | $2.46M | 0.00% | +573,840+113.5% | Added |
| Acadian Asset Management LLC | 928,205 | $2.11M | 0.01% | +494,496+114.0% | Added |
| State Street Corp | 827,956 | $1.89M | 0.00% | +666,850+413.9% | Added |
| Qube Research & Technologies Ltd | 800,511 | $1.83M | 0.00% | +476,045+146.7% | Added |
| Raymond James & Associates | 797,677 | $1.82M | 0.00% | −5,158−0.6% | Reduced |
| D. E. Shaw & Co., Inc. | 767,066 | $1.75M | 0.00% | −18,193−2.3% | Reduced |